Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

Oncotarget

Volumn 8, Issue 13, 2017, Pages 21539-21553

  de Coaña, Yago Pico ^a   Wolodarski, Maria ^a,b   Poschke, Isabel ^c   Yoshimoto, Yuya ^d   Yang, Yuan ^a,e   Nyström, Maria ^a   Edbäck, Ulrika ^a   Brage, Suzanne Eghyazi ^a   Lundqvist, Andreas ^a,f   Masucci, Giuseppe V ^a,b   Hansson, Johan ^a,b   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e GUIZHOU MEDICAL UNIVERSITY   (China)

^f NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

CD8 effector memory T cells; Checkpoint blockade; Ipilimumab; MDSC; Melanoma

Indexed keywords

CD15 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CORTICOSTEROID; HLA DR ANTIGEN; IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; EFFECTOR CELL; EOSINOPHIL COUNT; FEMALE; FLOW CYTOMETRY; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; MEMORY T LYMPHOCYTE; MYELOID-DERIVED SUPPRESSOR CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IPILIMUMAB; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELLS; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85016401544     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15368     Document Type: Article

References (49)

1. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23: 6043-53. doi: 10.1200/JCO.2005.06.205.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23. doi: 10.1056/NEJMoa1003466.
3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015; 33: 1889-94. doi: 10.1200/JCO.2014.56.2736.
4. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013; 18: 733-43. doi: 10.1634/theoncologist.2012-0483.
5. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15: 457-72. doi: 10.1038/nrc3973.
6. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-6.
7. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11: 852-63. doi: 10.1038/nri3108.
8. Pico de Coana Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, Masucci GV, Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res. 2013; 1: 158-62. doi: 10.1158/2326-6066.CIR-13-0016.
9. Sattui S, de la Flor C, Sanchez C, Lewis D, Lopez G, Rizo-Patron E, White AC, Jr., Montes M. Cryopreservation modulates the detection of regulatory T cell markers. Cytometry B Clin Cytom. 2012; 82: 54-8. doi: 10.1002/cyto.b.20621.
10. Florek M, Schneidawind D, Pierini A, Baker J, Armstrong R, Pan Y, Leveson-Gower D, Negrin R, Meyer E. Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease. PLoS One. 2015; 10: e0145763. doi: 10.1371/journal.pone.0145763.
11. Grutzner E, Stirner R, Arenz L, Athanasoulia AP, Schrodl K, Berking C, Bogner JR, Draenert R. Kinetics of human myeloid-derived suppressor cells after blood draw. J Transl Med. 2016; 14: 2. doi: 10.1186/s12967-015-0755-y.
12. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012; 381: 14-22. doi: 10.1016/j. jim.2012.04.004.
13. Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, Brandau S. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 2013; 19: 328-36. doi: 10.1177/1753425912463618.
14. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677-704. doi: 10.1146/annurev. immunol.26.021607.090331.
15. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439: 682-7. doi: 10.1038/nature04444.
16. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443: 350-4. doi: 10.1038/nature05115.
17. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745-63. doi: 10.1146/annurev.immunol.22.012703.104702.
18. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70: 4335-45. doi: 10.1158/0008-5472. CAN-09-3767.
19. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Buttner P, Garbe C, Pawelec G. Myeloid-derived suppressor cells predict survival of advanced melanoma patients: comparison with regulatory T cells and NY-ESO-1-or Melan-A-specific T cells. Clin Cancer Res. 2013; 20: 1601-9. doi: 10.1158/1078-0432. CCR-13-2508.
20. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol. 2012; 144: 250-68. doi: 10.1016/j.clim.2012.06.003.
21. Martens A, Wistuba-Hamprecht K, Foppen MG, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-15-2412.
22. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014; 63: 247-57. doi: 10.1007/s00262-013-1508-5.
23. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin Cancer Res. 2015; 21: 5453-9. doi: 10.1158/1078-0432.CCR-15-0676.
24. Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Mizrahi O, Saragovi A, Shtainberg H, Lotem M, Baniyash M. Clinical significance of circulating CD33+CD11b+HLA-DR-myeloid cells in Stage-IV melanoma patients treated with ipilimumab. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-15-3104.
25. Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 2014; 7: 203-9. doi: 10.2147/OTT.S57335.
26. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010; 25: 601-13. doi: 10.1089/cbr.2010.0865.
27. Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014; 71: 161-9. doi: 10.1016/j. jaad.2014.02.035.
28. Schindler K, Harmankaya K, Kuk D, Mangana J, Michielin O, Hoeller C, Dummer R, Pehamberger H, Wolchok JD, Postow MA. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. ASCO Meeting Abstracts. 2014; 32: 9096.
29. McCullough J, Wieblen BJ, Peterson PK, Quie PG. Effects of temperature on granulocyte preservation. Blood. 1978; 52: 301-10.
30. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012; 35: 89-97. doi: 10.1097/CJI.0b013e31823aa41c.
31. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. Cancer Immunol Res. 2013; 1: 229-34. doi: 10.1158/2326-6066.CIR-13-0020.
32. Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, Wong HK. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014; 15: 25-32. doi: 10.1038/gene.2013.57.
33. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25: 2546-53. doi: 10.1200/JCO.2006.08.5829.
34. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic selftolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyteassociated antigen 4. J Exp Med. 2000; 192: 303-10.
35. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013; 210: 1695-710. doi: 10.1084/jem.20130579.
36. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015; 112: 6140-5. doi: 10.1073/pnas.1417320112.
37. Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK. Expression of CTLA-4 by human monocytes. Scand J Immunol. 2002; 55: 53-60.
38. Wang XB, Fan ZZ, Anton D, Vollenhoven AV, Ni ZH, Chen XF, Lefvert AK. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC immunology. 2011; 12: 21. doi: 10.1186/1471-2172-12-21.
39. Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, Capanni P, Polito L, Ratta M, Pileri S, Piccioli M, Basso G, Rissotto L, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood. 2003; 101: 202-9. doi: 10.1182/blood-2002-06-1668.
40. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008; 135: 234-43. doi: 10.1053/j. gastro.2008.03.020.
41. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011; 117: 6532-41. doi: 10.1182/blood-2010-11-317321.
42. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012; 130: 1109-19. doi: 10.1002/ijc.26123.
43. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008; 68: 5439-49. doi: 10.1158/0008-5472.CAN-07-6621.
44. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8: 765-72.
45. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013; 14: 1212-8. doi: 10.1038/ni.2762.
46. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009; 206: 3015-29. doi: 10.1084/jem.20090847.
47. Chen X, Fosco D, Kline DE, Meng L, Nishi S, Savage PA, Kline J. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol. 2014; 44: 2603-16. doi: 10.1002/eji.201344423.
48. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Buttner P, Garbe C, Pawelec G. Myeloidderived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or melan-A-specific T cells. Clin Cancer Res. 2014; 20: 1601-9. doi: 10.1158/1078-0432. CCR-13-2508.
49. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7: e51862. doi: 10.1371/journal.pone.0051862.